Literature DB >> 22178462

Alternative therapeutic approaches to chronic proton pump inhibitor treatment.

Ronnie Fass1.   

Abstract

Chronic consumption of proton pump inhibitors (PPIs) by patients with gastroesophageal reflux disease is very common, primarily because of their potent and profound effect on acid secretion that results in an unsurpassed rate of symptom resolution and esophageal healing. However, there have been a growing number of reports over the past few years about various side effects caused by chronic PPI treatment. Concerns have been raised by patients and physicians alike about the common practice of prescribing PPIs, often more than once daily, on a long-term basis. As a result, there has been a resurgence of interest in alternative therapeutic modalities for chronic PPI treatment. These include novel endoscopic and surgical techniques, as well as other available therapeutic strategies that are likely to be revisited, such as histamine-2-receptor antagonists, intermittent and on-demand PPI treatment, and antireflux surgery, among others. Copyright Â
© 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178462     DOI: 10.1016/j.cgh.2011.12.020

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  12 in total

1.  Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later.

Authors:  Mark Noar; Patrick Squires; Emmanuelle Noar; Martin Lee
Journal:  Surg Endosc       Date:  2014-02-22       Impact factor: 4.584

Review 2.  Esophageal motility abnormalities in gastroesophageal reflux disease.

Authors:  Irene Martinucci; Nicola de Bortoli; Maria Giacchino; Giorgia Bodini; Elisa Marabotto; Santino Marchi; Vincenzo Savarino; Edoardo Savarino
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

3.  Elimination of Dietary Triggers Is Successful in Treating Symptoms of Gastroesophageal Reflux Disease.

Authors:  Cesare Tosetti; Edoardo Savarino; Edoardo Benedetto; Rudi De Bastiani
Journal:  Dig Dis Sci       Date:  2020-06-24       Impact factor: 3.199

4.  Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.

Authors:  Joel E Richter
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

5.  Unmet Needs in the Treatment of Gastroesophageal Reflux Disease.

Authors:  Ram Dickman; Carla Maradey-Romero; Rachel Gingold-Belfer; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 4.924

6.  Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.

Authors:  Kafia Belhocine; Fabienne Vavasseur; Christelle Volteau; Laurent Flet; Yann Touchefeu; Stanislas Bruley des Varannes
Journal:  BMC Gastroenterol       Date:  2014-07-15       Impact factor: 3.067

7.  The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum.

Authors:  Zilla H Hussain; Emily E Henderson; Carla Maradey-Romerao; Nina George; Ronnie Fass; Brian E Lacy
Journal:  Clin Transl Gastroenterol       Date:  2015-08-13       Impact factor: 4.488

8.  Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Authors:  Kiyoshi Ashida; Katsuhiko Iwakiri; Naoki Hiramatsu; Yuuichi Sakurai; Tetsuharu Hori; Kentarou Kudou; Akira Nishimura; Eiji Umegaki
Journal:  World J Gastroenterol       Date:  2018-04-14       Impact factor: 5.742

Review 9.  New and future drug development for gastroesophageal reflux disease.

Authors:  Carla Maradey-Romero; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2013-12-30       Impact factor: 4.924

10.  Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.

Authors:  K Ashida; Y Sakurai; T Hori; K Kudou; A Nishimura; N Hiramatsu; E Umegaki; K Iwakiri
Journal:  Aliment Pharmacol Ther       Date:  2015-11-11       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.